comparemela.com

Latest Breaking News On - Zhiqiang shu - Page 1 : comparemela.com

These drug companies are going nuclear to fight cancer

Big pharma’s investments in nuclear medicine highlight how cancer treatment is shifting to targeted approaches.

Novartis pluvictoVictor bultoBristol myers squibbEli lillyZhiqiang shuSeagen incDrug administrationFusion pharmaceuticalsVisible alphaPoint biopharmaPerspective therapeuticsLaurion capitalBiologics engineeringOncology targeted deliveryPharma companiesBig pharma

StockWatch: Pfizer Scales Patent Cliff by Pursuing Seagen Deal

Pfizer's interest in acquiring Seagen stems from a need to recoup patent cliff revenue losses by replenishing its pipeline, analysts say.

Gregory renzaReni benjaminAndrew berensBerenberg zhiqiang shuBill dunnAsthika goonewardeneMatthew harrisonDane leoneAstellas pharmaMichael schmidtTeresa buracchioJosh schimmerMerck seagenRaymond jamesJay olsonEtzer darout

Affimed N V (NASDAQ:AFMD) Q1 2023 Earnings Call Transcript

Operator: Good day, everyone and welcome to Affimed s First Quarter 2023 Earnings and Corporate Update Call. At this time, all participants are in a listen-only mode.

United statesWolfgang fischerAlex fudukidisZhiqiang shuSrikripa devarakondaSwayampakula ramakanthArndt schotteliusLi watsekDenise muellerAndreas harstrickYanan zhuMaurice raycroftBradley caninoAngus smithBrad caninoAdi hoess

BIONTECH : Berenberg reiterates its Buy rating

Zhiqiang Shu from Berenberg retains his positive opinion on the stock with a Buy rating. The target price continues to be set at USD 200. | May 18, 2023

Zhiqiang shuBiontech se stock exchangePress releaseSd bntx us09075v1026

Seagen (SGEN) Receives a Hold from Berenberg Bank

Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Seagen (SGEN – Research Report) today and set a price target of $229.00. T.

Stifel nicolausAlnylam pharmaZhiqiang shuBerenberg bankSeagen incResearch report

vimarsana © 2020. All Rights Reserved.